Recent advances in congenital ichthyoses

Current Opinion in Pediatrics

Volumn 27, Issue 4, 2015, Pages 473-479

  Hernández Martín, Angela ^a   González Sarmiento, Rogelio ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

enzyme replacement therapy; ichthyosis with confetti; Keywords congenital ichthyoses; peeling skin disease; severe dermatitis, multiple allergies and metabolic wasting syndrome; topical N acetyl cysteine

Indexed keywords

ACETYLCYSTEINE; CYTOKERATIN 10; CYSTEINE; DERMATOLOGICAL AGENT;

CELL ADHESION; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); CONGENITAL ICHTHYOSIFORM ERYTHRODERMA; DERMATITIS; DESMOSOME; ENZYME REPLACEMENT; EVIDENCE BASED PRACTICE; GENE MUTATION; GENOTYPE; HUMAN; KERATINOCYTE; MECHANICAL STRESS; NETHERTON DISEASE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SKIN ABRASION; SKIN ALLERGY; SYSTEMATIC REVIEW (TOPIC); SYSTEMIC THERAPY; TOPICAL TREATMENT; WASTING SYNDROME; DOMINANT GENE; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC PREDISPOSITION; GENETICS; ICHTHYOSIFORM ERYTHRODERMA, CONGENITAL; IMMUNOLOGY; MUTATION; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECESSIVE GENE; TOPICAL DRUG ADMINISTRATION; TRENDS;

ADMINISTRATION, TOPICAL; CYSTEINE; DERMATOLOGIC AGENTS; GENE EXPRESSION REGULATION; GENES, DOMINANT; GENES, RECESSIVE; GENETIC PREDISPOSITION TO DISEASE; GENETIC THERAPY; HUMANS; ICHTHYOSIFORM ERYTHRODERMA, CONGENITAL; MUTATION; PHENOTYPE; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84959523852     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0000000000000239     Document Type: Review

References (47)

1. Oji V, Tadini G, Akiyama M, et al. Revised nomenclature and classification of inherited ichthyoses: results of the First Ichthyosis Consensus Conference in Soreze 2009. J Am Acad Dermatol 2010; 63: 607-641
2. Hernandez-Martin A, Aranegui B, Martin-Santiago A, Garcia-Doval I. A systematic review of clinical trials of treatments for the congenital ichthyoses, excluding ichthyosis vulgaris. J Am Acad Dermatol 2013; 69: 544-549; e548
3. Petrof G, Mellerio JE, McGrath JA. Desmosomal genodermatoses. Br J Dermatol 2012; 166: 36-45
4. Lundstrom A, Serre G, Haftek M, Egelrud T. Evidence for a role of corneodesmosin, a protein which may serve to modify desmosomes during cornification, in stratum corneum cell cohesion and desquamation. Arch Dermatol Res 1994; 286: 369-375
5. Deraison C, Bonnart C, Lopez F, et al. LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction. Mol Biol Cell 2007; 18: 3607-3619
6. Briot A, Deraison C, Lacroix M, et al. Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. J Exp Med 2009; 206: 1135-1147
7. Samuelov L, Sarig O, Harmon RM, et al. Desmoglein 1 deficiency results in severe dermatitis, multiple allergies and metabolic wasting. Nat Genet 2013; 45: 1244-1248
8. Oji V, Eckl KM, Aufenvenne K, et al. Loss of corneodesmosin leads to severe skin barrier defect, pruritus, and atopy: unraveling the peeling skin disease. Am J Hum Genet 2010; 87: 274-281
9. Chavanas S, Bodemer C, Rochat A, et al. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet 2000; 25: 141-142
10. Milingou M, Wood P, Masouye I, et al. Focal palmoplantar keratoderma caused by an autosomal dominant inherited mutation in the desmoglein 1 gene. Dermatology 2006; 212: 117-122
11. Keren H, Bergman R, Mizrachi M, et al. Diffuse nonepidermolytic palmoplantar keratoderma caused by a recurrent nonsense mutation in DSG1. Arch Dermatol 2005; 141: 625-628
12. Mazereeuw-Hautier J, Leclerc EA, Simon M, et al. A novel mutation in CDSN causes peeling skin disease in a patient from Morocco. Br J Dermatol 2011; 165: 1152-1155
13. Mallet A, Kypriotou M, George K, et al. Identification of the first nonsense CDSN mutation with expression of a truncated protein causing peeling skin syndrome type B. Br J Dermatol 2013; 169: 1322-1325
14. Teye K, Hamada T, Krol RP, et al. Homozygous deletion of six genes including corneodesmosin on chromosome 6p21.3 is associated with generalized peeling skin disease. J Dermatol Sci 2014; 75: 36-42
15. Levy-Nissenbaum E, Betz RC, Frydman M, et al. Hypotrichosis simplex of the scalp is associated with nonsense mutations in CDSN encoding corneodesmosin. Nat Genet 2003; 34: 151-153
16. Bowden PE. Peeling skin syndrome: genetic defects in late terminal differentiation of the epidermis. J Invest Dermatol 2011; 131: 561-564
17. Komatsu N, Suga Y, Saijoh K, et al. Elevated human tissue kallikrein levels in the stratum corneum and serum of peeling skin syndrome-type B patients suggests an over-desquamation of corneocytes. J Invest Dermatol 2006; 126: 2338-2342
18. Garty BZ, Nimri R. Hypothyroidism in Netherton syndrome. Pediat Dermatol 2008; 25: 134-135
19. Soreide K, Soiland H, Korner H, et al. Acute pancreatitis in a young girl with the Netherton syndrome. J Pediat Surg 2005; 40: e69-e72
20. Macknet CA, Morkos A, Job L, et al. An infant with Netherton syndrome and persistent pulmonary hypertension requiring extracorporeal membrane oxygenation. Pediat Dermatol 2008; 25: 368-372
21. Samuelov L, Sprecher E. Peeling off the genetics of atopic dermatitis-like congenital disorders. J Allergy Clin Immunol 2014; 134: 808-815
22. Hanifin JM, Butler JM, Chan SC. Immunopharmacology of the atopic diseases. J Invest Dermatol 1985; 85: 161s-164s
23. Kubo A, Nagao K, Amagai M. Epidermal barrier dysfunction and cutaneous sensitization in atopic diseases. J Clin Invest 2012; 122: 440-447
24. Schuttelaar ML, Kerkhof M, Jonkman MF, et al. Filaggrin mutations in the onset of eczema, sensitization, asthma, hay fever and the interaction with cat exposure. Allergy 2009; 64: 1758-1765
25. Ishida-Yamamoto A, Igawa S. Genetic skin diseases related to desmosomes and corneodesmosomes. J Dermatol Sci 2014; 74: 99-105
26. Choate KA, Lu Y, Zhou J, et al. Mitotic recombination in patients with ichthyosis causes reversion of dominant mutations in KRT10. Science 2010; 330: 94-97
27. Krunic AL, Palcesky D, Busbey S, Medenica M. Congenital reticular ichthyosiform erythroderma-ichthyosis variegata: a case report and review of the literature. Acta Dermato-venereol 2003; 83: 36-39
28. Brusasco A, Cambiaghi S, Tadini G, et al. Unusual hyperpigmentation developing in congenital reticular ichthyosiform erythroderma (ichthyosis variegata). Br J Dermatol 1998; 139: 893-896
29. Marghescu S, Anton-Lamprecht I, Rudolph PO, Kaste R. Congenital reticular ichthyosiform erythroderma. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 1984; 35: 522-529
30. Torrelo A, Marrero MD, Mediero IG, et al. Progressive macular leucoderma in a patient with congenital ichthyosiform erythroderma. Br J Dermatol 2001; 144: 1280-1282
31. Brusasco A, Tadini G, Cambiaghi S, et al. A case of congenital reticular ichthyosiform erythroderma-ichthyosis'en confettis'. Dermatology 1994; 188: 40-45
32. Burger B, Spoerri I, Schubert M, et al. Description of the natural course and clinical manifestations of ichthyosis with confetti caused by a novel KRT10 mutation. Br J Dermatol 2012; 166: 434-439
33. Spoerri I, Brena M, De Mesmaeker J, et al. The phenotypic and genotypic spectra of ichthyosis with confetti plus novel genetic variation in the 3-end of KRT10: from disease to a syndrome. JAMA Dermatol 2015; 151: 64-69
34. Choate KA, Milstone LM. Phenotypic expansion in ichthyosis with confetti. JAMA Dermatol 2015; 151: 15-16
35. Torma H. Regulation of keratin expression by retinoids. Dermatoendocrinol 2011; 3: 136-140
36. Van Wauwe J, Van Nyen G, Coene MC, et al. Liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic effects in vivo. J Pharmacol Exp Therap 1992; 261: 773-779
37. Ahmad M. Study on cytochrome p-450 dependent retinoic acid metabolism and its inhibitors as potential agents for cancer therapy. Sci Pharm 2011; 79: 921-935
38. Vahlquist A, Blockhuys S, Steijlen P, et al. Oral liarozole in the treatment of patients with moderate/severe lamellar ichthyosis: results of a randomized, double-blind, multinational, placebo-controlled phase II/III trial. Br J Dermatol 2014; 170: 173-181
39. Sekharam M, Trotti A, Cunnick JM, Wu J. Suppression of fibroblast cell cycle progression in G1 phase by N-acetylcysteine. Toxicol Appl Pharmacol 1998; 149: 210-216
40. Redondo P, Bauza A. Topical N-acetylcysteine for lamellar ichthyosis. Lancet 1999; 354: 1880
41. Davila-Seijo P, Florez A, Davila-Pousa C, et al. Topical N-acetylcysteine for the treatment of lamellar ichthyosis: an improved formula. Pediat Dermatol 2014; 31: 395-397
42. Bassotti A, Moreno S, Criado E. Successful treatment with topical N-acetylcysteine in urea in five children with congenital lamellar ichthyosis. Pediat Dermatol 2011; 28: 451-455
43. Gicquel JJ, Vabres P, Dighiero P. Use of topical cutaneous N-acetylcysteine in the treatment of major bilateral ectropion in an infant with lamellar ichthyosis. J Fr Ophtal 2005; 28: 412-415
44. Sarici SU, Sahin M, Yurdakok M. Topical N-acetylcysteine treatment in neonatal ichthyosis. Turk J Pediat 2003; 45: 245-247
45. Deffenbacher B. Successful experimental treatment of congenital ichthyosis in an infant. BMJ Case Rep 2013
46. De Leeuw J, De Vijlder HC, Bjerring P, Neumann HA. Liposomes in dermatology today. J Eur Acad Dermatol Venereol 2009; 23: 505-516
47. Aufenvenne K, Larcher F, Hausser I, et al. Topical enzyme-replacement therapy restores transglutaminase 1 activity and corrects architecture of transglutaminase-1-deficient skin grafts. Am J Hum Genet 2013; 93: 620-630